Affinage

SLC16A10

Monocarboxylate transporter 10 · UniProt Q8TF71

Length
515 aa
Mass
55.5 kDa
Annotated
2026-04-28
81 papers in source corpus 16 papers cited in narrative 16 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SLC16A10 (MCT10/TAT1) is a proton-gradient-independent facilitated diffusion uniporter that mediates bidirectional transport of aromatic amino acids (tryptophan, phenylalanine, tyrosine) and thyroid hormones (T3, T4) across basolateral membranes of kidney proximal tubule, intestinal epithelium, liver, skeletal muscle, and thyroid gland (PMID:16245314, PMID:23045339, PMID:24248460). In epithelia, TAT1-mediated aromatic amino acid recycling functionally cooperates with the LAT2/CD98hc obligatory exchanger to drive net neutral amino acid efflux without requiring direct physical interaction between the two transporters, and double knockout of TAT1 and LAT2 produces greater aminoaciduria than either single knockout (PMID:17273864, PMID:29610403). In vivo, SLC16A10 is required for systemic aromatic amino acid homeostasis, tissue-specific thyroid hormone efflux that shapes the serum thyroid hormone profile, cochlear sensory epithelium development (in concert with MCT8), age-dependent bone remodeling, and UVB-induced melanogenesis through phenylalanine uptake into melanocytes (PMID:23045339, PMID:24248460, PMID:29535325, PMID:34669927, PMID:39171634). In skeletal muscle, SLC16A10 is the most abundantly expressed thyroid hormone transporter and is transcriptionally regulated by the homeodomain factor Six1, linking its expression to fast-twitch muscle fiber identity and thyroid hormone–dependent gene programs (PMID:34809717).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2005 Medium

    Establishing human TAT1 as an aromatic amino acid transporter co-localizing with LAT2 at the renal basolateral membrane resolved where and in what combination these transporters operate in human kidney.

    Evidence Functional expression, Northern blot, and immunohistochemistry in human kidney tissue

    PMID:15918515

    Open questions at the time
    • Single-lab study
    • No efflux kinetics measured
    • No in vivo loss-of-function
  2. 2006 High

    Demonstrating that TAT1 operates as a facilitated diffusion uniporter with symmetrical influx/efflux kinetics — rather than as a proton-coupled or exchange transporter — established the mechanistic basis for its role as a basolateral efflux pathway for aromatic amino acids.

    Evidence Influx and efflux assays in Xenopus oocytes, immunofluorescence in mouse kidney and intestine

    PMID:16245314

    Open questions at the time
    • No structural basis for uniport mechanism
    • No in vivo validation of essentiality
  3. 2007 High

    Showing that TAT1 and LAT2-4F2hc functionally cooperate — TAT1-mediated aromatic amino acid recycling drives net neutral amino acid efflux through the obligatory exchanger — without physical interaction explained how two independent transporters coordinate basolateral amino acid efflux.

    Evidence Xenopus oocyte co-expression, HPLC amino acid analysis, co-immunoprecipitation (negative for physical interaction), mutagenesis of inactive surface-expressed mutants

    PMID:17273864

    Open questions at the time
    • Oocyte system may not fully recapitulate epithelial polarity
    • No in vivo confirmation of cooperation
  4. 2011 Medium

    Characterizing MCT10's ability to transport the affinity-label BrAc-T3 and establishing differential inhibitor profiles versus MCT8 provided initial tools to distinguish thyroid hormone handling by the two related transporters.

    Evidence Radiolabeled BrAc-T3 transport assay in transfected cells, mass spectrometry

    PMID:21315799

    Open questions at the time
    • No substrate-bound structure to explain selectivity differences
    • Covalent labeling approach was negative
  5. 2012 High

    The TAT1 knockout mouse demonstrated that SLC16A10 is essential in vivo for aromatic amino acid homeostasis — its loss causes elevated plasma aromatic amino acids, aromatic aminoaciduria under high-protein diet, and impaired hepatic uptake — validating the uniporter model in a whole-organism context.

    Evidence TAT1 knockout mouse, plasma/tissue amino acid quantification, in vivo 123I-2-I-L-Phe kidney accumulation, everted gut sac assay

    PMID:23045339

    Open questions at the time
    • No human genetic disorder linked
    • Compensatory transporter upregulation not fully mapped
  6. 2013 High

    Using Mct10 single and Mct8/Mct10 double knockout mice revealed that MCT10 mediates thyroid hormone efflux from liver, kidney, and thyroid — and that its loss contributes to the characteristic serum T4 profile of MCT8 deficiency — establishing MCT10 as a physiologically relevant thyroid hormone transporter distinct from MCT8.

    Evidence Mct10 KO and Mct8/Mct10 double KO mice, serum and tissue thyroid hormone measurements, hypothalamic TRH expression

    PMID:24248460

    Open questions at the time
    • Relative contributions of MCT10 to T3 vs. T4 transport in each tissue not fully resolved
    • Mechanism of tissue-specific directionality unclear
  7. 2016 Medium

    Showing that MCT10 overexpression potently stimulates T3 metabolism by D3 at the cell periphery but does not augment nuclear T3 receptor-mediated transcription clarified that MCT10 primarily controls T3 availability at the plasma membrane rather than in the nuclear compartment.

    Evidence Co-transfection in JEG3 cells with T3-responsive reporter and D3 metabolic assay

    PMID:27492966

    Open questions at the time
    • JEG3 is a trophoblast-derived cell line; relevance to physiological target tissues not confirmed
    • No direct measurement of nuclear T3 concentrations
  8. 2017 Medium

    Identification of N81K as a transport-dead mutant that retains normal surface expression localized a critical residue within the putative substrate trajectory, providing the first structure–function insight into the MCT10 transport path.

    Evidence Functional complementation in yeast, localization in HEK293T cells, homology modeling

    PMID:28754537

    Open questions at the time
    • Based on homology model, not experimentally determined structure
    • Only one residue characterized
  9. 2018 High

    Double knockout of Mct8 and Mct10 in mice produced hearing loss and retarded cochlear sensory epithelium development — rescued by T3 administration — establishing that these two transporters together are required for thyroid hormone delivery to the developing cochlea.

    Evidence Slc16a2/Slc16a10 double KO mice, auditory brainstem response, histology, T3 rescue

    PMID:29535325

    Open questions at the time
    • Individual contributions of MCT10 versus MCT8 to cochlear TH delivery not separated
    • Cellular identity of TH-dependent cochlear targets not defined
  10. 2018 High

    In vivo double knockout of TAT1 and LAT2 produced greater aminoaciduria than either single KO and revealed compensatory y+LAT1/CD98hc upregulation, confirming the functional cooperation model in the intact kidney and demonstrating amino acid transporter network plasticity.

    Evidence TAT1/LAT2 double KO mice, urine amino acid analysis, transporter mRNA and protein quantification

    PMID:29610403

    Open questions at the time
    • Additional compensatory transporters likely exist but were not exhaustively catalogued
    • No human genetic confirmation of the cooperative model
  11. 2021 Medium

    Demonstrating that Six1 directly binds the Slc16a10 enhancer and is required for MCT10 expression in fast-twitch skeletal muscle — where MCT10 is the dominant thyroid hormone transporter — connected muscle fiber-type transcriptional programs to thyroid hormone responsiveness through MCT10.

    Evidence ChIP-seq for Six1, in vivo RNAi knockdown in mouse tibialis anterior, thyroid hormone reporter assay

    PMID:34809717

    Open questions at the time
    • Whether Six1 regulation of MCT10 applies to other MCT10-expressing tissues is unknown
    • Downstream TH-responsive targets mediating fiber-type effects not identified
  12. 2021 Medium

    Finding that Mct10 deficiency disrupts canonical basolateral TSH receptor localization in thyrocytes — shifting it to vesicular compartments — revealed an unexpected role for MCT10 in maintaining thyroid gland signaling architecture beyond simple hormone transport.

    Evidence Mct10 KO and combinatorial KO mouse models, immunofluorescence for TSH receptor

    PMID:34071318

    Open questions at the time
    • Mechanism linking MCT10 loss to TSH receptor mislocalization is unknown
    • Whether this is a direct or indirect effect is unresolved
  13. 2022 Medium

    MCT10 deficiency produced age- and site-dependent trabecular bone changes with altered osteoblast differentiation, and these effects were eliminated by concurrent MCT8 loss, indicating MCT10 modulates bone remodeling through thyroid hormone–dependent pathways that are counterbalanced by MCT8.

    Evidence Mct10 KO and Mct8/Mct10 double KO mice, microCT, histomorphometry, in vitro osteoblast assay

    PMID:34669927

    Open questions at the time
    • Mechanism by which MCT8 loss rescues bone phenotype unclear
    • Osteoclast-specific role of MCT10 not characterized
  14. 2024 Medium

    SLC16A10 was shown to promote melanogenesis by supplying phenylalanine to melanocytes, with UVB-induced upregulation driving melanin production — extending the physiological scope of SLC16A10 beyond epithelial and endocrine tissues to skin pigmentation.

    Evidence Overexpression and siRNA knockdown in MNT1 melanocytes, melanin quantification, targeted metabolomics

    PMID:39171634

    Open questions at the time
    • In vivo relevance in skin not confirmed
    • Whether other aromatic amino acid transporters compensate in melanocytes unknown
  15. 2024 High

    Cryo-EM structures of thyroxine-bound MCT10 in the inward-facing state revealed gate residues and conformational changes consistent with an alternating-access mechanism, providing the first experimental structural framework for understanding substrate selectivity and transport cycle.

    Evidence (preprint) Cryo-EM structure determination of thyroxine-bound human MCT10

    PMID:bio_10.1101_2024.10.17.618737

    Open questions at the time
    • Outward-facing and occluded states not yet captured
    • Structure is from a preprint awaiting peer review
    • Aromatic amino acid-bound structures not determined

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for MCT10's dual substrate specificity (aromatic amino acids vs. thyroid hormones), the complete transport cycle conformational landscape, whether human loss-of-function variants cause a Mendelian disorder, and the mechanism by which MCT10 loss alters TSH receptor localization in thyrocytes.
  • No human disease-causing mutations identified
  • No outward-facing or occluded-state structures
  • Mechanism of TSH receptor mislocalization unknown
  • Tissue-specific regulation beyond Six1 not characterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005215 transporter activity 8
Localization
GO:0005886 plasma membrane 4
Pathway
R-HSA-382551 Transport of small molecules 7
Partners
SLC16A2SLC3A2SLC7A8

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2006 TAT1 (SLC16A10) functions as a facilitated diffusion uniporter for aromatic amino acids (Trp, Phe, Tyr) at basolateral membranes, mediating net efflux without requiring an exchange substrate. The transporter shows symmetrical selectivity and apparent affinity for influx and efflux, and localizes to basolateral membranes of small intestine enterocytes, kidney proximal tubule, and sinusoidal side of perivenous hepatocytes. It is not N-glycosylated. Xenopus oocyte expression system (influx/efflux assays), real-time RT-PCR, immunofluorescence localization in mouse kidney and intestine Journal of cellular physiology High 16245314
2007 TAT1 (SLC16A10) and LAT2-4F2hc (SLC7A8-SLC3A2) cooperate functionally: TAT1-mediated aromatic amino acid recycling drives net efflux of other neutral amino acids via LAT2-4F2hc exchanger. Both transporters co-localize in early kidney proximal tubule basolateral membranes. Physical interaction between the two transporters is not required for functional cooperation. Xenopus oocyte co-expression system, HPLC amino acid analysis, immunofluorescence co-localization, co-immunoprecipitation and crosslinking (negative result for physical interaction), functional mutagenesis of inactive surface-expressed mutants Pflugers Archiv : European journal of physiology High 17273864
2005 Human TAT1 (hTAT1/SLC16A10) transports aromatic amino acids and co-localizes with hLAT2 at the basolateral membrane of renal proximal tubule, consistent with cooperative roles in renal reabsorption of neutral amino acids. Functional expression, Northern blot, immunohistochemistry in human kidney Archives of pharmacal research Medium 15918515
2012 TAT1 (Slc16a10) knockout mice display elevated plasma, muscle, and kidney aromatic amino acid concentrations and major aromatic aminoaciduria under high-protein diet, demonstrating that TAT1 is required for equilibrating aromatic amino acid concentrations across basolateral membranes of kidney and intestinal epithelial cells and for enabling hepatocytes to act as a sink for extracellular aromatic amino acid homeostasis. TAT1 knockout mouse model, plasma/tissue amino acid measurements, in vivo 123I-2-I-L-Phe kidney accumulation, ex vivo everted gut sac assay, mRNA quantification of amino acid transporters The Journal of physiology High 23045339
2013 Mct10 (Slc16a10) facilitates thyroid hormone (TH) efflux from liver, kidneys, and thyroid gland. In Mct8/Mct10 double knockout mice, serum T4 is partially normalized (rescued) compared to Mct8 single KO, while the hyperthyroid state in peripheral tissues is exacerbated, demonstrating that Mct10 participates in tissue-specific TH efflux and contributes to the serum TH profile characteristic of Mct8 deficiency. Mct10 single KO and Mct8/Mct10 double KO mouse models, serum and tissue TH measurements, hypothalamic TRH expression analysis Endocrinology High 24248460
2018 Loss of both Slc16a2 (Mct8) and Slc16a10 (Mct10) in mice results in hearing loss, retarded development of the cochlear sensory epithelium similar to hypothyroidism, progressive degeneration of cochlear hair cells, and loss of endocochlear potential. T3 administration largely restores sensory epithelium development, indicating that both transporters are required for thyroid hormone delivery to the cochlea. Slc16a2/Slc16a10 double KO mouse model, auditory brainstem response testing, histology, T3 rescue experiment Scientific reports High 29535325
2018 TAT1 (SLC16A10) and LAT2/CD98hc functionally cooperate in vivo for renal reabsorption of aromatic and other neutral amino acids. Double KO (dKO LAT2-TAT1) mice show greater aminoaciduria than either single KO, with additional loss of cationic amino acids. y+LAT1/CD98hc is upregulated as a compensatory mechanism in dKO mice. Double KO mouse model (TAT1 and LAT2), urine amino acid analysis, transporter mRNA and protein expression analysis Journal of the American Society of Nephrology : JASN High 29610403
2017 Human MCT10 (SLC16A10) mediates tryptophan transport via facilitated diffusion (proton-gradient independent) in a yeast heterologous expression system. The N81K SNP completely abrogates tryptophan import without affecting expression or plasma membrane localization. N81 is located within the putative tryptophan trajectory in the modeled structure. Functional complementation in S. cerevisiae tat2Δtrp1 cells, growth assays, localization in HEK293T cells, structure modeling Biochimica et biophysica acta. Biomembranes Medium 28754537
2016 MCT10 (SLC16A10) and MCT8 both facilitate T3 efflux from cells. Overexpression of MCT10 potently stimulates T3 metabolism by type 3 deiodinase (D3) at the cell periphery but does not augment steady-state nuclear T3 receptor-mediated transcription, indicating that MCT10 primarily affects T3 availability at the plasma membrane rather than in the nucleus. Transient transfection in JEG3 cells, T3-responsive luciferase reporter assay, type 3 deiodinase metabolic assay, co-transfection with CRYM Molecular and cellular endocrinology Medium 27492966
2021 The transcription factor Six1 directly binds an enhancer in the Slc16a10 (Mct10) gene locus and is required for full MCT10 expression in adult skeletal muscle (tibialis anterior). MCT10 is the most abundantly expressed thyroid hormone transporter in skeletal muscle, with higher expression in fast-twitch than slow-twitch muscle. Loss of MCT10 in tibialis anterior reduces thyroid hormone receptor-dependent transcription and recapitulates Six1 effects on fast-twitch muscle gene expression. ChIP-seq (genome-wide Six1 location), gene expression profiling, in vivo RNAi knockdown in mouse tibialis anterior, RT-PCR, thyroid hormone reporter assay Skeletal muscle Medium 34809717
2021 Mct10 (Slc16a10) deficiency in mice causes vesicular (non-canonical) TSH receptor localization in thyrocytes instead of basolateral localization, and reduces dead thyrocyte numbers. This effect is reversed by additional cathepsin K deficiency. The data indicate that MCT10 is required to maintain canonical basolateral TSH receptor localization and normal thyrocyte turnover. Single and multiple KO mouse models (Mct10-/-, Ctsk-/-, Mct8-/y combinations), immunofluorescence for TSH receptor localization, histology International journal of molecular sciences Medium 34071318
2022 MCT10 (SLC16A10) deficiency in male mice causes age- and site-dependent changes in trabecular bone mass: decreased trabecular bone volume at 12 weeks, but increased bone volume at 24 weeks, with altered osteoblast and osteoclast numbers. In vitro, Mct10 deficiency impairs osteoblast differentiation and activity. Mct8/Mct10 double KO eliminates these bone effects. Mct10 KO and Mct8/Mct10 double KO mouse models, microCT, histomorphometry, in vitro osteoblast differentiation assay Endocrinology Medium 34669927
2011 MCT10 (SLC16A10) and MCT8 both transport the affinity-label BrAc[125I]T3 but are not covalently modified by it. Both transporters facilitate BrAc[125I]T3 transport across the plasma membrane. Differential inhibitory profiles of iodothyronine derivatives on T3 transport by MCT8 vs. MCT10 were identified. Transport assay with radiolabeled BrAc-T3 in transfected cells, mass spectrometry for labeled protein identification Molecular and cellular endocrinology Medium 21315799
2024 SLC16A10 promotes melanogenesis in melanocytes by facilitating uptake of phenylalanine. SLC16A10 overexpression increases melanin synthesis and upregulates melanogenesis-related proteins (TYR, TYRP1) at the protein but not RNA level. SLC16A10 expression is upregulated by UVB irradiation, and knockdown reduces UVB-induced melanin production and phenylalanine uptake. SLC16A10 overexpression and siRNA knockdown in MNT1 melanocytes, melanin quantification, western blot, targeted metabolomics, ELISA, gene expression datasets (GSE72140, GSE67098) Experimental dermatology Medium 39171634
2024 miR-21-5p directly targets SLC16A10 (confirmed by dual luciferase reporter assay). miR-21-5p overexpression reduces LPS-induced inflammatory cytokine expression (IL-1β, TNF-α) in A549 alveolar epithelial cells, and siRNA knockdown of SLC16A10 similarly reduces inflammation. Co-transfection of miR-21-5p inhibitor and si-SLC16A10 rescues the inhibitor's pro-inflammatory effect, placing SLC16A10 downstream of miR-21-5p in this pathway. Luciferase reporter assay, miRNA mimic/inhibitor transfection, siRNA knockdown, RT-qPCR, western blot in A549 cells Scientific reports Medium 38750066
2024 Cryo-EM structures of human MCT10 (SLC16A10) in the inward-facing thyroxine-bound state were determined. Structural analysis revealed a network of conserved gate residues involved in conformational changes upon thyroxine binding that trigger ligand release on the opposite membrane compartment, consistent with an alternating-access mechanism. Cryo-EM structure determination of thyroxine-bound human MCT10 in inward-facing state bioRxivpreprint High bio_10.1101_2024.10.17.618737

Source papers

Stage 0 corpus · 81 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1996 A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. The Journal of urology 215 8911360
1994 Two FK506 resistance-conferring genes in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid permeases mediating tyrosine and tryptophan uptake. Molecular and cellular biology 136 7523855
2008 Role of C. elegans TAT-1 protein in maintaining plasma membrane phosphatidylserine asymmetry. Science (New York, N.Y.) 114 18436785
2005 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU international 97 16153204
2009 Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. Journal of molecular endocrinology 94 19541799
1998 Potential retroviruses in plants: Tat1 is related to a group of Arabidopsis thaliana Ty3/gypsy retrotransposons that encode envelope-like proteins. Genetics 93 9611185
2014 Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 86 25030736
2003 Pressure-induced differential regulation of the two tryptophan permeases Tat1 and Tat2 by ubiquitin ligase Rsp5 and its binding proteins, Bul1 and Bul2. Molecular and cellular biology 83 14560004
2006 Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions as an efflux pathway. Journal of cellular physiology 75 16245314
2001 Tat1, a novel sulfate transporter specifically expressed in human male germ cells and potentially linked to rhogtpase signaling. The Journal of biological chemistry 75 11278976
2013 Tissue-specific alterations in thyroid hormone homeostasis in combined Mct10 and Mct8 deficiency. Endocrinology 71 24248460
2010 Mechanisms of recurrence of Ta/T1 bladder cancer. Annals of the Royal College of Surgeons of England 71 20522307
2017 Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment - Data Using a Blind, Randomized, Clinical Study. European thyroid journal 69 28785541
2011 The testis anion transporter TAT1 (SLC26A8) physically and functionally interacts with the cystic fibrosis transmembrane conductance regulator channel: a potential role during sperm capacitation. Human molecular genetics 69 22121115
2012 T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control. The Journal of physiology 62 23045339
2007 Aminophospholipid translocase TAT-1 promotes phosphatidylserine exposure during C. elegans apoptosis. Current biology : CB 58 17540571
2008 The C. elegans P4-ATPase TAT-1 regulates lysosome biogenesis and endocytosis. Traffic (Copenhagen, Denmark) 56 18939953
2007 Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. British journal of cancer 53 17505513
2018 TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth. Nature communications 46 29703898
2004 A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. The Journal of urology 43 14665865
2019 Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Archiv : an international journal of pathology 41 31240474
2018 Deafness and loss of cochlear hair cells in the absence of thyroid hormone transporters Slc16a2 (Mct8) and Slc16a10 (Mct10). Scientific reports 39 29535325
2009 The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 39 19344635
2013 Tissue distribution and thyroid hormone effects on mRNA abundance for membrane transporters Mct8, Mct10, and organic anion-transporting polypeptides (Oatps) in a teleost fish. Comparative biochemistry and physiology. Part A, Molecular & integrative physiology 38 24113777
2007 Recycling of aromatic amino acids via TAT1 allows efflux of neutral amino acids via LAT2-4F2hc exchanger. Pflugers Archiv : European journal of physiology 37 17273864
2005 Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Archives of pharmacal research 37 15918515
1991 Transient occurrence of extrachromosomal DNA of an Arabidopsis thaliana transposon-like element, Tat1. Proceedings of the National Academy of Sciences of the United States of America 37 1850833
2019 TAT1 and TAT2 tyrosine aminotransferases have both distinct and shared functions in tyrosine metabolism and degradation in Arabidopsis thaliana. The Journal of biological chemistry 35 30630953
2008 Intra-accumbal Tat1-72 alters acute and sensitized responses to cocaine. Pharmacology, biochemistry, and behavior 35 18582493
2005 Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 34 15667865
2006 HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. European urology 31 16828965
2006 Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. European urology 30 17027141
2006 Cyclin D3 expression in primary Ta/T1 bladder cancer. The Journal of pathology 29 16482499
2005 Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. The Prostate 27 15651064
2002 Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer 26 12216091
2018 Cooperation of Antiporter LAT2/CD98hc with Uniporter TAT1 for Renal Reabsorption of Neutral Amino Acids. Journal of the American Society of Nephrology : JASN 25 29610403
2017 miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. Genes, chromosomes & cancer 24 29181884
2016 Effects of thyroid hormone transporters MCT8 and MCT10 on nuclear activity of T3. Molecular and cellular endocrinology 22 27492966
2003 DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 19 12809927
2022 Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation. The Journal of cell biology 18 36222836
2013 Pressure-induced endocytic degradation of the Saccharomyces cerevisiae low-affinity tryptophan permease Tat1 is mediated by Rsp5 ubiquitin ligase and functionally redundant PPxY motif proteins. Eukaryotic cell 18 23666621
2003 Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. Journal of clinical pathology 18 12783972
2017 Functional analysis of human aromatic amino acid transporter MCT10/TAT1 using the yeast Saccharomyces cerevisiae. Biochimica et biophysica acta. Biomembranes 16 28754537
2006 Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici Foundation. Urologia internationalis 15 16888422
1999 The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. International urology and nephrology 15 10668939
2022 Vimentin inhibits α-tubulin acetylation via enhancing α-TAT1 degradation to suppress the replication of human parainfluenza virus type 3. PLoS pathogens 14 36108090
2015 Intra-ventral tegmental area HIV-1 Tat1-86 attenuates nicotine-mediated locomotor sensitization and alters mesocorticolimbic ERK and CREB signaling in rats. Frontiers in microbiology 14 26150803
1998 TAT1 encodes a low-affinity histidine transporter in Saccharomyces cerevisiae. Biochemical and biophysical research communications 14 9473505
2021 Matrix stiffness regulates α-TAT1-mediated acetylation of α-tubulin and promotes silica-induced epithelial-mesenchymal transition via DNA damage. Journal of cell science 13 33310909
2006 Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. Urology 13 16566978
2013 Inactivation of Caenorhabditis elegans aminopeptidase DNPP-1 restores endocytic sorting and recycling in tat-1 mutants. Molecular biology of the cell 11 23427264
2008 Expression of maspin in papillary Ta/T1 bladder neoplasms. Anticancer research 11 18383887
2002 Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1. Leukemia 10 11840295
2013 Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. Urologic oncology 9 23790536
2011 The thyroid hormone transporters MCT8 and MCT10 transport the affinity-label N-bromoacetyl-[(125)I]T3 but are not modified by it. Molecular and cellular endocrinology 9 21315799
2009 REG1A predicts recurrence in stage Ta/T1 bladder cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 9 19167858
2019 Variants in MCT10 protein do not affect FT3 levels in athyreotic patients. Endocrine 8 31280469
2007 Sequence analysis of mRNA transcripts encoding Jembrana disease virus Tat-1 in vivo. Virus research 8 18096262
2024 MiR-21-5p modulates LPS-induced acute injury in alveolar epithelial cells by targeting SLC16A10. Scientific reports 7 38750066
2022 The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice. Endocrinology 7 34669927
2019 ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. Journal of cancer research and clinical oncology 7 31595333
2009 High yield expression and purification of HIV-1 Tat1-72 for structural studies. Journal of virological methods 7 19941902
2024 The amino acid transporter SLC16A10 promotes melanogenesis by facilitating the transportation of phenylalanine. Experimental dermatology 6 39171634
2021 Six1 promotes skeletal muscle thyroid hormone response through regulation of the MCT10 transporter. Skeletal muscle 6 34809717
2019 Structure and function analysis of the C. elegans aminophospholipid translocase TAT-1. Journal of cell science 6 30683797
2022 Substrate-induced differential degradation and partitioning of the two tryptophan permeases Tat1 and Tat2 into eisosomes in Saccharomyces cerevisiae. Biochimica et biophysica acta. Biomembranes 5 35031272
1995 A Simple and Rapid TAR-Dependent in vitro Transcription Assay Using T Cell Nuclear Extracts and Synthetic tat1-86 Protein. Journal of biomedical science 5 11725049
2025 TAT-1, a phosphatidylserine flippase, affects molting and regulates membrane trafficking in the epidermis of Caenorhabditis elegans. Genetics 4 39722491
2021 Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma. Molecular and clinical oncology 4 34984103
2019 Objectifying grade in Ta-T1 urothelial carcinomas of the bladder using proliferative and quantitative markers: A multicentre study in 310 bladder tumors. Urologic oncology 4 30935844
2024 Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank. The Journal of clinical endocrinology and metabolism 3 37740545
2022 Structure elucidation and gene cluster annotation of the O-antigen of Halomonas titanicae TAT1 containing three residues of 2,3-diacetamido-2,3-dideoxy-D-glucuronic acid. Carbohydrate research 3 35998422
1993 Intravesical mitoxantrone in superficial bladder tumours (Ta-T1). European journal of cancer (Oxford, England : 1990) 3 8260250
2025 Role of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2 40919667
2021 Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10. Biomedicines 1 33946552
2021 The Amino Acid Transporter Mct10/Tat1 Is Important to Maintain the TSH Receptor at Its Canonical Basolateral Localization and Assures Regular Turnover of Thyroid Follicle Cells in Male Mice. International journal of molecular sciences 1 34071318
2006 New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladder. TheScientificWorldJournal 1 17619741
2025 Differentiation of Isomeric TAT1-CARNOSINE Peptides by Energy-Resolved Mass Spectrometry and Principal Component Analysis. Molecules (Basel, Switzerland) 0 40005164
2025 Uncovering CD248, MMP28, and SLC16A10 in Sjögren's disease: a machine learning-driven SHAP approach for CD4+ T cell-associated biomarker discovery. Clinical and experimental rheumatology 0 41328587
2024 TAT-1, a phosphatidylserine flippase, affects molting and regulates membrane trafficking in the epidermis of C. elegans. bioRxiv : the preprint server for biology 0 39314363
1995 Idarubicin in the intravesical treatment of superficial transitional-cell carcinoma of the bladder (ta-t1) - a phase I-ii study. Oncology reports 0 21597859